Haleon plc (HLN) Stock Price & Analysis
Haleon plc (HLN) closed at USD 10.37 on Thursday, October 22, 2026, up 3.49% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 10.02; the Oct 22, 2026 session ranged USD 10.12–10.4 on volume of 14,622,369 shares. Market capitalization is $45.60B, with a 52-week range of USD 8.65–11.28 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:15 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HLN.md
Key facts (HLN)
- 5 of 80 tracked superinvestors hold HLN (13F, Q2 2026): 0 new, 3 added, 1 reduced, 1 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 11.93 (range 10–13.77).
- Total return with dividends: 1Y +12.9% vs S&P 500 +14.9%; 5Y +57.9% vs S&P 500 +80.3%.
- Next earnings: 2026-07-30, EPS estimate USD —, revenue estimate $2.92B.
Superinvestors (SEC 13F-HR, Q2 2026) (HLN)
5 of 80 tracked investors hold HLN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 0.73% | $1.40B | Added +2.3% |
| Bill Nygren | Oakmark Funds | 0.21% | $157M | Added +12.0% |
| Kahn Brothers | Kahn Brothers Group | 0.10% | $565K | Unchanged |
| First Eagle Investment | First Eagle Investment Management | 0.07% | $39.4M | Added +4.8% |
| Tweedy Browne | 0.05% | $672K | Reduced -1.0% |
Analysts (HLN)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 11.93 (low 10, high 13.77).
Total return (dividends reinvested) (HLN)
| 1Y (from 2025-10-23) | 5Y (from 2022-07-25) | |
|---|---|---|
| Total return | +12.9% | +57.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +12.9% | +11.3% |
| Volatility (annualized) | 23.4% | 22.8% |
| Max drawdown | -21.8% (Feb 2026→Jun 2026) | -24.6% (Aug 2022→Aug 2022) |
HLN suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Pfizer (PFE) | “The Group has received notices of potential claims for indemnification relating to OTC Zantac arising out of the Stock and Asset Purchase Agreement (SAPA), which the Group has rejected on the basis that the scope of the indemnities set out in the SAPA only covers the Consumer Healthcare businesses of GSK and Pfizer as conducted when their Consumer Healthcare joint venture was formed in 2018.” |
Quoted from the company's 20-F filed Mar 13, 2026.
HLN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $2.92B | — |
| Next quarter (ends Dec 2026) | — | — | — | $2.88B | — |
| Current fiscal year (ends Dec 2026) | $0.56 | $0.55 | +2.2% | $11.39B | 3 |
| Next fiscal year (ends Dec 2027) | $0.62 | $0.61 | +1.3% | $11.87B | 3 |
HLN options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 38.7% | ±9.6% |
| Feb 19, 2027 | 119 | 26.3% | ±21.0% |
| May 21, 2027 | 210 | 25.6% | ±15.7% |
30-day implied volatility 31% vs 24.9% realized over the last 30 trading days. Put/call ratio (volume) 0.07. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:15 UTC)
| Price | USD 10.37 |
|---|---|
| Change | ▲ 3.49% (up) |
| Previous Close | USD 10.02 |
| Open | USD 10.13 |
| Day Range | USD 10.12 – 10.4 |
| 52-Week Range | USD 8.65 – 11.28 |
| Volume | 14,622,369 shares |
| Market Cap | $45.60B |
| Exchange | NYQ |
Technical Analysis (HLN)
Nexqual's technical model rates HLN "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:15 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.75 (overbought) |
| vs SMA50 | Above (USD 9.55) |
| MACD | 0.22 (positive) |
Analyst Ratings (HLN)
Wall Street analysts rate HLN "Buy" based on 5 analysts, with a mean price target of USD 11.93 (range USD 10–13.77), per Nexqual as of October 23, 2026 at 09:15 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11.93 |
| High Target | USD 13.77 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 3 / 2 / 0 |
Earnings (HLN)
| Next Earnings Date | 2026-07-30 |
|---|---|
| Revenue Estimate | $2.92B |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
Financials & Fundamentals (HLN)
| Total Revenue | $11.15B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.20% |
| Gross Margin | +65.57% |
| Operating Margin | +23.94% |
| Profit Margin | +14.55% |
| ROE | +10.09% |
| Debt / Equity | 0.5 |
| Current Ratio | 0.69 |
| Total Cash | $826.00M |
| Total Debt | $8.25B |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
Financial Health Score (HLN)
Nexqual rates Haleon plc's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:15 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 24% (last 12 months) |
| Balance Sheet | Mixed — GBP 826M cash vs GBP 8.25B debt |
| Cash Flow | Solid — Operating cash flow GBP 2.65B (TTM) |
| Efficiency | Mixed — ROE 10%, ROA 5.1% |
Ownership (HLN)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +13.64% |
| Shares Outstanding | 4.40B |
| Float | 4.43B |
| Short % of Float | +0.56% |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
Leadership (HLN)
Haleon plc is led by Brian James McNamara, CEO & Executive Director, per Nexqual as of October 23, 2026 at 09:15 UTC.
| CEO & Executive Director | Brian James McNamara |
|---|---|
| CFO & Director | Dawn Amanda Allen |
| Chief Marketing Officer | Tamara Jane Rogers |
| President of EMEA & LatAm | Filippo Lanzi |
| President of Asia Pacific | Keith Choy |
Major Backers & Investors (HLN)
Notable institutional backers of Haleon plc include Dodge & Cox Inc., FMR, LLC, Fidelity, according to Nexqual as of October 23, 2026 at 09:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 3.4% |
| FMR, LLC | 2.75% |
| Fidelity | 1.19% |
| ClearBridge Investments, LLC | 0.73% |
| Morgan Stanley | 0.44% |
| Harris Associates L.P. | 0.38% |
| Harding Loevner LP | 0.35% |
| Arrowstreet Capital, Limited Partnership | 0.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Nuveen | 0.35% |
Source: Nexqual, October 23, 2026 at 09:15 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries | USD 40.21 | ▼ 1.01% |
| ZTS | Zoetis Inc. | USD 82 | ▲ 2.99% |
| TAK | Takeda Pharmaceutical Company L | USD 20.36 | ▲ 2.16% |
| UTHR | United Therapeutics Corporation | USD 584.79 | ▲ 3.78% |
| VTRS | Viatris Inc. | USD 18.48 | ▲ 0.16% |
| NBIX | Neurocrine Biosciences, Inc. | USD 143.29 | ▲ 1.4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:15 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt